Yet, the rate and extent of adoption of flow cytometric analysis for quantifying peripheral blood neutrophil MPO expression in patients with suspected MDS will be determined by issues of cost-effectiveness. The gene discussed is MPO; the disease is myelodysplastic syndrome.